Immunovant IMVT

HealthcareMarket cap $4B1 connection

Immunovant develops batoclimab - an FcRn inhibitor that reduces levels of harmful IgG antibodies in autoimmune diseases. FcRn inhibition is a novel mechanism targeting thyroid eye disease, myasthenia gravis, and other antibody-mediated conditions. The mechanism can potentially treat dozens of autoimmune diseases with a single drug class.

Explore Immunovant on the interactive map Relationship timeline Find a path to another company

Owned by 1

Companies with a stake in Immunovant

Roivant SciencesHealthcare · $8BRoivant Sciences is majority owner of Immunovant

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Immunovant's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=IMVT" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Immunovant on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.